The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck
โ Scribed by O'Brien, M.; Schofield, J.B.; Lorentzos, A.; Moore, J.; Atkinson, H.; Henk, J.M.; MacLennan, K.A.; Gore, M.E.
- Book ID
- 123028014
- Publisher
- Elsevier Science
- Year
- 1994
- Tongue
- English
- Weight
- 308 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0964-1955
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi
Patients with locally advanced, inoperable squamous cell carcinoma of the head and neck were offered three courses of cisplatin and 96-h 5-fluorouracil (5-FU) infusion. Subsequent therapy included surgery when feasible, irradiation therapy, and a maintenance program of methotrexate (MTX)-5-FU. Thirt
## Abstract ## Background. Intraoperative manipulation of the tumor during cancer surgery has long been recognized as a source of metastasis and contamination of the surgical wound during tumor removal. We explored the use of intraoperative chemotherapy to minimize the risk of tumor cell implantat